
Athenex ATNX
Quartalsbericht 2022-Q3
hinzugefügt 06.06.2026
Athenex Langfristiger Schuldenstrom 2011-2026 | ATNX
Langfristiger Schuldenstrom Jährlich Athenex
| 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2.09 M | 2.48 M | 3.18 M | 3.01 M | 779 K | 835 K | 766 K | - | - | - | - | - |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 3.18 M | 766 K | 1.88 M |
Langfristiger Schuldenstrom anderer Aktien in der Arzneimittelhersteller
| Name | Langfristiger Schuldenstrom | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
Endo International plc
ENDP
|
956 K | - | - | $ 28.9 M | ||
|
Evoke Pharma
EVOK
|
59.5 K | - | - | $ 36.6 M | ||
|
Cumberland Pharmaceuticals
CPIX
|
468 K | $ 5.6 | - | $ 83.2 M | ||
|
HEXO Corp.
HEXO
|
914 K | - | 2.45 % | $ 38.1 M | ||
|
Calliditas Therapeutics AB (publ)
CALT
|
12.5 M | - | -0.1 % | $ 2.03 B | ||
|
AcelRx Pharmaceuticals
ACRX
|
100 K | - | 7.5 % | $ 6.35 M | ||
|
DURECT Corporation
DRRX
|
1.08 M | - | - | $ 50.1 M | ||
|
Adamis Pharmaceuticals Corporation
ADMP
|
343 K | - | 0.86 % | $ 117 M | ||
|
Aerie Pharmaceuticals
AERI
|
4.36 M | - | - | $ 754 M | ||
|
Agile Therapeutics
AGRX
|
366 K | - | 10.11 % | $ 58.2 M | ||
|
Alimera Sciences
ALIM
|
634 K | - | - | $ 142 M | ||
|
Cronos Group
CRON
|
337 K | $ 2.63 | -1.87 % | $ 1.01 B | ||
|
Harrow Health
HROW
|
887 K | $ 38.93 | 3.43 % | $ 1.43 B | ||
|
Avadel Pharmaceuticals plc
AVDL
|
582 K | - | - | $ 2.06 B | ||
|
Catalent
CTLT
|
13 M | - | - | $ 11.5 B | ||
|
Organogenesis Holdings
ORGO
|
4.95 M | $ 2.41 | 2.99 % | $ 305 M | ||
|
Eagle Pharmaceuticals
EGRX
|
1.53 M | - | -39.89 % | $ 27.7 M | ||
|
Pacira BioSciences
PCRX
|
8.89 M | $ 22.74 | -1.09 % | $ 1.05 B | ||
|
Canopy Growth Corporation
CGC
|
7.46 M | $ 0.98 | -1.71 % | $ 105 M | ||
|
Sonoma Pharmaceuticals
SNOA
|
58 K | $ 1.11 | 1.83 % | $ 1.38 M | ||
|
Aurora Cannabis
ACB
|
5.38 M | $ 2.95 | -2.96 % | $ 162 M | ||
|
Solid Biosciences
SLDB
|
2.1 M | $ 7.36 | 3.08 % | $ 644 M | ||
|
Jupiter Wellness
JUPW
|
23.5 K | - | - | $ 33.6 M | ||
|
Lannett Company
LCI
|
2.06 M | - | 1.15 % | $ 7.11 M | ||
|
OrganiGram Holdings
OGI
|
1.03 M | $ 1.03 | -2.83 % | $ 98.2 M | ||
|
Tilray
TLRY
|
2.47 M | $ 5.01 | 0.6 % | $ 3.1 B | ||
|
Evolus
EOLS
|
2.53 M | $ 6.75 | 0.3 % | $ 435 M | ||
|
Sundial Growers
SNDL
|
35.5 M | $ 1.43 | 0.7 % | $ 3.37 M | ||
|
Emergent BioSolutions
EBS
|
2.4 M | $ 8.29 | -0.36 % | $ 444 M | ||
|
Veru
VERU
|
759 K | $ 3.13 | 4.33 % | $ 45.8 M | ||
|
Neoleukin Therapeutics
NLTX
|
3.05 M | - | - | $ 193 M | ||
|
cbdMD
YCBD
|
778 K | $ 0.67 | -2.33 % | $ 2.7 M | ||
|
Assertio Holdings
ASRT
|
240 K | $ 23.5 | 0.09 % | $ 150 M | ||
|
ProPhase Labs
PRPH
|
1.21 M | - | - | $ 5.07 M | ||
|
Radius Health
RDUS
|
613 K | - | - | $ 1.42 B | ||
|
Bausch Health Companies
BHC
|
61 M | $ 4.99 | -1.38 % | $ 1.85 B | ||
|
PetIQ
PETQ
|
7.61 M | - | 1.64 % | $ 400 M | ||
|
Recro Pharma
REPH
|
1.1 M | - | -4.76 % | $ 65.3 M | ||
|
OptiNose
OPTN
|
1.25 M | - | - | $ 1.08 B | ||
|
SCYNEXIS
SCYX
|
483 K | $ 4.09 | -3.31 % | $ 204 M | ||
|
PLx Pharma
PLXP
|
622 K | - | -27.8 % | $ 2.56 M | ||
|
Viatris
VTRS
|
109 M | $ 16.32 | -0.97 % | $ 19 B | ||
|
Zomedica Corp.
ZOM
|
717 K | - | -0.21 % | $ 98 M | ||
|
Zynerba Pharmaceuticals
ZYNE
|
215 K | - | - | $ 55.5 M | ||
|
Rockwell Medical
RMTI
|
1.16 M | $ 0.64 | 2.74 % | $ 23 M | ||
|
Tricida
TCDA
|
2.74 M | - | - | $ 3.25 M | ||
|
China Pharma Holdings
CPHI
|
71.6 K | $ 0.75 | 2.35 % | $ 3.22 M | ||
|
TherapeuticsMD
TXMD
|
975 K | $ 2.28 | 3.64 % | $ 26.4 M |